Franklin Biotechnology Discovery Fund

This fund or share class has been closed to new investors.

PRICE AND YTD RETURN As of 04/29/2016

NAV down $-3.56 $128.17
POP $135.99
YTD Total return at Nav -21.63%
1 YEAR RETURN -34.39%
5 YEAR RETURN 17.69%
10 YEAR RETURN 10.41%


Investment Category Sector
Distributions Annually
CUSIP 354 713 844
Fund Number 402
Inception Date Sep 15, 1997
Total Net Assets (all share classes) As of 03/31/2016 $1,160.7 (M)
Distribution Rate at NAV N/A
30-Day Standardized yield N/A

SALES CHARGE, EXPENSES, & FEES As of 09/01/2015 (updated annually)

Gross Expense Ratio 1.00%
Net Expense Ratio 1.00%
Max Initial Sales Charge 5.75%
CDSC 0.00%
12b-1 Fee 0.25%

Fund Description

The fund seeks capital appreciation by investing at least 80% of its net assets in securities of biotechnology companies and discovery research firms including those involved in fields such as genomics, genetic engineering, and gene therapy, as well as health care, pharmaceuticals and agriculture.

Strategy Statement

"With the increasing demand for new medical treatments driving earnings growth, and many profitable firms to choose from, we believe now is an exciting time to invest in the biotechnology sector."

Evan McCulloch, CFA®


Evan McCulloch, CFA

Evan McCulloch, CFA®

  • Joined Franklin Templeton in 1992
  • Managed Fund Since 1997
Steve Kornfeld, CFA, MBA

Steve Kornfeld, CFA®, MBA

  • Joined Franklin Templeton in 2001
  • Managed Fund Since 2015

Overall Morningstar Rating As of 03/31/2016

Rating Category: Health

The fund's overall Morningstar Rating measures risk-adjusted returns and is derived from a weighted average of the performance figures associated with its 3-, 5- and 10-year (if applicable) rating metrics.

Historical Morningstar Rating As of 03/31/2016

Years Ratings Funds
in category
1 Stars
2 Stars
2 Stars

Morningstar Style Box As of 12/31/2015

Strategy, Benefits, Results


  • We take a bottom-up approach to individual stock selection.
  • We look for companies that possess products with favorable competitive profiles, large market opportunities and strong intellectual property.
  • We favor companies with excellent management, strong financial characteristics and attractive valuations.
  • Our San Francisco Bay Area location is shared by many leading biotechnology companies, enabling us to easily attend scientific meetings and symposia, and to consult with community and academic physicians.


  • Participate in trends moving markets. Invest in innovative sectors—technology, medicine, global communications—we believe are poised for long-term growth.
  • Diversification. By adding investments from different sectors to your portfolio, you may take advantage of expanding and contracting economic cycles.
  • Experienced management. Same lead portfolio manager since the fund's inception in 1997.

You need Adobe Acrobat Reader 6.0 or higher to view and print PDF documents. Download a free version from Adobe's website.